利伐沙班治疗脑梗死患者的有效性与安全性研究  

Study of efficacy and safety of rivaroxaban in the treatment of patients with cerebral infarction

作　　者：高蕊 洪雁[1] 何云燕[1] GAO Rui;HONG Yan;HE Yun-yan(Department of Fifth Ward of Neurology,Tianjin Huanhu Hospital,Tianjin 300060,China)

机构地区：[1]天津市环湖医院神经内科五病区,天津300060

出　　处：《中国城乡企业卫生》2021年第11期22-24,共3页Chinese Journal of Urban and Rural Enterprise Hygiene

基　　金：天津市卫生行业重点攻关项目(16KG160)。

摘　　要：目的探讨新型口服抗凝药利伐沙班治疗非瓣膜性房颤脑梗死患者的有效性及安全性。方法选取2017年10月—2019年10月天津市环湖医院收治的非瓣膜性房颤脑梗死患者100例,随机将患者分为对照组和观察组各50例。对照组患者给予华法林治疗,观察组患者给予利伐沙班治疗,所有患者均治疗12个月,记录两组患者应用抗凝药物后栓塞事件发生率、mRS评分≤2分占比、出血事件、死亡事件及不良反应发生率。结果两组血栓栓塞事件发生率、mRS评分≤2分患者占比比较,差异均无统计学意义(P>0.05)。观察组出血事件发生率和死亡率分别为8.00%和0.00%,低于对照组的14.00%和4.00%,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论利伐沙班在非瓣膜性房颤脑梗死患者中的应用,能明显降低出血事件及死亡事件发生率,安全性较好,具有较高的临床应用价值。Objective To investigate the efficacy and safety of the new oral anticoagulant rivaroxaban in the treatment of patients with nonvalvular atrial fibrillation and cerebral infarction.Methods From October2017 to October 2019,100 patients with nonvalvular atrial fibrillation and cerebral infarction admitted to Tianjin Huanhu Hospital were selected and randomly divided into control group and observation group,with 50 cases in each group.The patients in the control group were treated with warfarin and the patients in the observation group were treated with rivaroxaban.All patients were treated for 12 months.The incidence of embolic events,the proportion of m RS score≤2 score,the incidences of bleeding events,death events and adverse reactions of two groups were recorded.Results There were no significant differences in the incidence of thromboembolic events and the proportion of patients with m RS score≤2 score between the two groups(P>0.05).The incidences of bleeding events and mortality in the observation group were 8.00%and 0.00%,which were lower than 14.00%and 4.00%in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of rivaroxaban in patients with nonvalvular atrial fibrillation and cerebral infarction could significantly reduce the incidences of bleeding events and death events,which had good safety and high clinical value.

关 键 词：非瓣膜性房颤 利伐沙班 华法林 抗凝 有效性 安全性 

分 类 号：R741.05[医药卫生—神经病学与精神病学]